novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Company profile
Ticker
NBY
Exchange
Website
CEO
Justin Hall
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
DERMAdoctor, LLC ...
IRS number
680454536
NBY stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
26 Mar 24
8-K
Completion of Acquisition or Disposition of Assets
26 Mar 24
8-K
Entry into a Material Definitive Agreement
25 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Entry into a Material Definitive Agreement
10 Jan 24
D
$554.81 k in options / securities to be acquired, sold $554.81 k, 5 investors
4 Jan 24
8-K
Entry into a Material Definitive Agreement
21 Dec 23
8-K
Departure of Directors or Certain Officers
11 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
UPLOAD
Letter from SEC
5 Oct 23
Transcripts
NBY
Earnings call transcript
2023 Q4
26 Mar 24
NBY
Earnings call transcript
2023 Q3
9 Nov 23
NBY
Earnings call transcript
2023 Q2
10 Aug 23
NBY
Earnings call transcript
2023 Q1
11 May 23
NBY
Earnings call transcript
2022 Q4
30 Mar 23
NBY
Earnings call transcript
2022 Q3
14 Nov 22
NBY
Earnings call transcript
2022 Q2
12 Aug 22
NBY
Earnings call transcript
2022 Q1
12 May 22
NBY
Earnings call transcript
2021 Q4
30 Mar 22
NBY
Earnings call transcript
2021 Q3
13 Nov 21
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Altium Capital Management LP
13 Feb 24
SC 13G/A
Hudson Bay Capital Management LP
6 Feb 24
4
Paul E. Freiman
13 Jun 23
4
Julie Garlikov
13 Jun 23
4
Yenyou Zheng
13 Jun 23
4
Yongxiang Zheng
13 Jun 23
4
Swan Sit
13 Jun 23
4
MIJIA WU
13 Jun 23
4
Paul E. Freiman
15 May 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.95 mm | 3.95 mm | 3.95 mm | 3.95 mm | 3.95 mm | 3.95 mm |
Cash burn (monthly) | 314.00 k | 6.00 k | 585.67 k | 1.25 mm | 121.00 k | 418.83 k |
Cash used (since last report) | 1.88 mm | 35.88 k | 3.50 mm | 7.45 mm | 723.66 k | 2.50 mm |
Cash remaining | 2.07 mm | 3.91 mm | 445.35 k | -3.51 mm | 3.22 mm | 1.44 mm |
Runway (months of cash) | 6.6 | 652.0 | 0.8 | -2.8 | 26.6 | 3.4 |
Institutional ownership, Q2 2023
0.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 3 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 8.57 mm |
Total shares | 56.33 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Renaissance Technologies | 44.92 k | $34.00 k |
Tower Research Capital | 11.19 k | $8.42 mm |
BAC Bank Of America | 86.00 | $65.00 k |
Advisor | 37.00 | $28.00 k |
Thrivent Trust Co of Tennessee | 37.00 | $0.00 |
BLK Blackrock | 20.00 | $15.00 k |
RY Royal Bank Of Canada | 15.00 | $0.00 |
MS Morgan Stanley | 9.00 | $7.00 k |
Addison Advisors | 4.00 | $4.00 k |
WealthPLAN Partners | 1.00 | $1.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Jun 23 | Sit Swan | RSU Common Stock | Grant | Acquire A | No | No | 0 | 858 | 0.00 | 858 |
9 Jun 23 | Freiman Paul E. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 858 | 0.00 | 858 |
9 Jun 23 | Wu Mijia | RSU Common Stock | Grant | Acquire A | No | No | 0 | 858 | 0.00 | 858 |
9 Jun 23 | Zheng Yenyou | RSU Common Stock | Grant | Acquire A | No | No | 0 | 858 | 0.00 | 858 |
9 Jun 23 | Julie Garlikov | RSU Common Stock | Grant | Acquire A | No | No | 0 | 858 | 0.00 | 858 |
News
NovaBay Pharmaceuticals: Q4 Earnings Insights
26 Mar 24
NovaBay Pharmaceuticals Q4 EPS $(0.21) Beats $(0.30) Estimate, Sales $3.73M Beat $3.40M Estimate
26 Mar 24
Earnings Scheduled For March 26, 2024
26 Mar 24
Novabay Reported Preliminary 2023 Sales Of $14.7M, Consisting Of $3.6M From Its DERMAdoctor Skincare Segment And $11.1M From Its Eyecare And Wound Care Segment Versus Consensus Of $14.40M
14 Mar 24
Novabay Reported Preliminary Q4 2023 Sales Of $3.7M, Consisting Of $0.9M From Its DERMAdoctor Skincare Segment And $2.8M From Its Eyecare And Wound Care Segment Versus Consensus Of $3.4M
14 Mar 24
Press releases
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
26 Mar 24
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
25 Mar 24
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
13 Mar 24
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
30 Jan 24
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor Network
9 Jan 24